The primary objective of the study is to assess the safety and tolerability of single dose of LEM-S401 in healthy adult subjects.

This study is designed to evaluate the safety and tolerability of LEM-S401 administered as subcutaneous injection in healthy adult subjects.

Overall, 18 subjects will be studied in 3 groups. Each subject will receive LEM-S401 or placebo subcutaneously.

Inclusion Criteria:

• Healthy male and female subjects aged 19 to ≤ 65 years at screening

Exclusion Criteria:

• Significant history or clinical manifestation of any hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematological, tumor, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, dermatological (eg, contact dermatitis, atopic dermatitis), or other
• History of drug abuse or positive urine drug screen at screening
• For all female subjects, pregnant (Urine-HCG positive) or breast-feeding subjects